doc. MUDr. Marek Trněný, CSc.
Pracoviště: I. interní klinika LF UK a VFN a ÚHKT (U nemocnice 1, 128 20 Praha)
E-mail: Marek.Trneny@uhkt.cz
Odborné práce publikované na Linkos.cz
Níže se zobrazuje autorství některých typů informací, které jsou součástí databazí na Linkos a také autorství článků pro pacienty na Linkos. Vypisují se knihy, články v Klinické onkologii a onkologické péči, tuzemská abstrakta zažazená do databáze abstrakt, brožury pro pacienty a také texty pro pacienty na Linkos. Rejstřík v žádném případě není úplným autorským rejstříkem, protože nejpodstatnější publikace a sice publikace v zahraničních časopisech tento způsob nezobrazuje.
Publikovaná abstrakta
- 5-Azacytidine and G-CSF Derepressed Chromatin Structure of PU.1 and Its Targets Cebpa and Cbfb In Myelodysplastic Syndrome (MDS)
- A RETROSPECTIVE STUDY TO ASSESS RELATIVE DOSE INTENSITIES IN PATIENTS WITH LYMPHOMA IN CENTRAL EUROPEAN COUNTRIES
- Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine
- Active Chromatin Structure near MYB Occupancy at the Mir-155 Host Gene Promoter Coincides with Increased Mir-155 and MYB Levels In Chronic Lymphocytic Leukemia
- Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry.
- ALTERATIONS OF CHEK2 GENE IN NON-HODGKIN LYMPHOMA PATIENTS
- ANALYSIS OF RISK FACTORS OF 248 PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS
- CD10 EXPRESSION IN LYMPH NODE STROMAL CELLS DOES NOT SIGNIFICANTLY INFLUENCE GENE EXPRESSION ANALYSIS OF CD10 POSITIVITY OR NEGATIVITY OF A TUMOR
- CLINICAL FINDINGS AND TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: THE ANALYSIS OF THE 1425 PATIENTS INCLUDED IN CZECH LYMPHOMA PROJECT (CLP)
- CLONAL EVOLUTION STUDIED BY I-FISH IN B-CLL
- Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DASATINIB EVEN AT LOWER DOSES IS AN EFFECTIVE FOR CHRONIC MYELOID LEUKAEMIA TREATMENT IN PATIENTS RESISTANT OR INTOLERANT TO IMATINIB
- DIAGNOSTIC AND THERAPEUTIC APPROACH TO SMALL LYMPHOCYTIC LYMPHOMA (SLL): EXPERIENCE OF CZECH LYMPHOMA STUDY GROUP
- Diagnostika lymfadenopatií průtokovou cytometrií
- Difuzní velkobuněčný B lymfom, charakteristika a léčba, data z registru Kooperativní lymfomové skupiny
- Disruption of a Functional Relationship Between PU.1 and Mir-155 during the Pathogenesis of Chronic Lymphocytic Leukemia (CLL)
- DISTINGUISHING OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION
- DISTINGUISHING OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA IN A GROUP OF DIFFUSE LARGE B-CELL LYMPHOMA USING GENE EXPRESSION OF SELECTED GENES
- DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study
- EFFECTS OF PRETRANSPLANTATION TREATMENT WITH RITUXIMAB ON OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA
- ENDOTHELIAL CELLS (EC) AND ENDOTHELIAL PRECURSOR CELLS (EPC) KINETICS IN HAEMATOLOGICAL PATIENTS UNDERGOING CHEMOTHERAPY OR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
- European MCL Network: An Update on Current First Line Trials.
- EXPRESSION OF CD66ABCE ON TUMOR CELLS IN NON-HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA
- Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
- FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
- IMMUNO CHEMOTHERAPY (ANTI CD20 AND FLUDARABIN/CYCLOPHOSPHAMIDE) AND HIGH DOSE CHEMOTHERAPY WITH ASCT INCREASES MOLECULAR REMISSION RATE BUT CANNOT PREVENT RELAPSES
- Impaired Peripheral Blood Dendritic Cell Counts in B-Chronic Lymphocytic Leukaemia
- Improving Survival in Patients with Chronic Lymphocytic Leukemia - Population Based Study
- Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study
- Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies
- INTENSIVE TREATMENT OF HIGH-RISK AGGRESSIVE B-CELL LYMPHOMAS WITH MEGACHOP-ESHAP-BEAM REGIMEN WITH OR WITHOUT RITUXIMAB: RESULTS OF THREE CONSECUTIVE TRIALS OF CLSG
- Intersticiální pneumonie jako projev toxicity kombinované léčby rituximabem, filgrastimem a cyklofosfamidem.
- Kooperativní lymfomová skupina (Czech Lymphoma Study Group)
- Léčba lymfomů CNS
- Léčba periferních T-nehodgkinských lymfomů v České republice
- LIMITED NUMBER OF GENES DISTINGUISHES BETWEEN GERMINAL CENTRE-LIKE AND NONGERMINAL CENTRE-LIKE DIFFUSE LARGE B CELL LYMPHOMA
- Lymfom z plášťových buněk - od zpřesnění diagnostiky k hledání účinné terapie
- Lymfoproliferativní choroby a solidní nádorová duplicita
- Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.
- Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era
- Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project
- MicroRNA Mir-155 and Myb Proto-Oncogene Family Members Cooperate in Pathogenesis of Chronic Lymphocytic Leukemia
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An Internatio
- PATTERN OF ANGIOGENESIS-RELATED GENE EXPRESSION DURING IN VIVO GROWTH OF MANTLE CELL LYMPHOMA CELL LINE JEKO-1
- Platelet-endothelial cell adhesion molecule (PECAM-1/CD31) is upregulated during growth of mantle cell lymphoma cell line JEKO-1 in immunodeficient mouse
- POSITIVE PRETRANSPLANTATION POSITRON EMISSION TOMOGRAPHY INDICATES POOR PROGNOSIS IN RELAPSED HODGKIN LYMPHOMA PATIENTS
- Postavení, přínos a možná úskalí integrovaného 18FDG PET/CT vyšetření u nemocných s ne-hodgkinskými lymfomy
- Prediction of outcome using positron emission tomography (PET) compared to standard response criteria and potential role in treatment decisions in diffuse large B-cell lymphoma (DLBCL) patients.
- Primární lymfomy centrálního nervového systému:data z registru kooperativní lymfové skupiny (KLS)
- Principy stagingu a hodnocení léčebné odpovědi u non-hodgkinských lymfomů
- R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma
- R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study
- R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.
- Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (
- Randomizovaná studie léčby mladých nemocných s nízce rizikovým difúzním velkobuněčným B lymfomem (DLBCL) s nízkým a srovnávající CHOP-like režim s rituximabem nebo bez rituximabu, (Mabthera International Trial, MInT). První analýza kompletní studie.
- Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT
- Relapse of Hodgkins lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT
- Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy.
- RITUXIMAB MAINTENANCE SIGNIFICANTLY PROLONGS DURATION OF REMISSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. FIRST RESULTS OF A RANDOMIZED TRIAL OF THE EUROPEAN MCL NETWORK
- RITUXIMAB SIGNIFICANLY IMPROVES THE OUTCOME OF YOUNG POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA - ON BEHALF OF CZECH LYMPHOMA STUDY GROUP
- Roscovitine Sensitizes Leukemia and Lymphoma Cells to TRAIL-Induced Apoptosis and Enhances Cell-Mediated Cytotoxicity
- Sledování klonálního vývoje u B-CLL metodou I-FISH
- SMALL LYMPHOCYTIC LYMPHOMA (SLL): RETROSPECTIVE ANALYSIS FROM THE REGISTRY OF CZECH LYMPHOMA STUDY GROUP
- SPONTANEOUS TRANSFORMATION OF LYMPH NODE AND BONE MARROW STROMAL CELLS FROM CANCER PATIENTS
- Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma
- The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- THE IMPACT OF THERAPY INTENSIFICATION AND OUTCOME OF 6 CML PATIENTS WITH THE SAME TYPE OF BCR-ABL MUTATION M244V
- THE OCCURRENCE OF CNS RELAPSES IN HIGH-RISK AGGRESSIVE LYMPHOMA PATIENS TREATED WITH INTENSIFIED INDUCTION AND HIGH-DOSE CONSOLIDATION PROTOCOLS OF THE CZECH LYMPHOMA STUDY GROUP
- The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG
- THE TREATMENT MODIFICATION DOES NOT SEEM TO CHANGE THE DLBCL PATIENT´S OUTCOME WHEN CORRELATED WITH EARLY PET RESULTS
- Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.
- VALUE OF 18F-FDG PET/CT FOR THE STAGING OF NON-HODGKIN´S LYMPHOMA: SIGNIFICANT IMPROVEMENT IN THE DETECTION OF NODAL AND EXTRANODAL LESIONS BUT MARGINAL IMPACT ON DISEASE STAGE
- Význam rituximabu v předtransplantační terapii na léčebné výsledky po autologní transplantaci u pacientů s difuzním velkobuněčným lymfomem.
- Základní principy léčby maligních lymfomů
Články v Klinické onkologii
- Distribuce podtypů non-hodgkinského lymfomu v České republice a jejich přežití
- Indikace k alogenním a autologním transplantacím krvetvorných buněk. Doporučení České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP.
- Léčba pacientů s relabovaným/refraktérním Hodgkinovým lymfomem
- Podávání interleukinu - 2 v časné fázi po autologní transplantaci krvetvorných buněk u nemocných s maligními lymfomy
- Primární testikulární lymfom, klinickopatologická multicentrická retrospektivní studie a data registru Kooperativní lymfomové skupiny (KLS)
- Současné postavení transplantace krvetvorných buněk v léčbě lymfomů – přehled
- Srovnávání účinnosti mobilizačního režimu s cyklofosfamidem + G-CSF a režimu IVE + G- CSF u nemocných s maligními lymfomy
- Určování rozsahu onemocnění u non-Hodgkinových lymfomů – doporučení Kooperativní lymfomové skupiny
- Vyšetření mediastina u nemocných s maligním lymfomem- využití tří zobrazovacícm metod: počítačové tomografie, galliové scintigrafie, magnetické rezonance. První výsledky.
- Význam klinického registru nemocných s lymfomy – přínos, možnosti a limitace
- Význam minimální reziduální nemoci a metody jejího stanovení u pacientů s některými hematologickými malignitami
- Význam selekce CD 34+ progenitorů u nemocných s non-Hodgkinským lymfomem léčených vysokodávkovanou chemoterapií s následnou autologní transplantací krvetvorných buněk
Stránky na Linkosu
Léčebné postupy
- Diagnostické a léčebné postupy u nemocných s maligními lymfomy II
- Minimální doporučená léčebná strategie u difuzního velkobuněčného B-nehodgkinského lymfomu (DLBCL)
- Minimální doporučená léčebná strategie u folikulárního lymfomu (FL)
- Minimální doporučená léčebná strategie u chronické lymfatické leukémie (CLL)